Nuclidium AG has raised CHF 26.4 million in an extension of its Series B round, totaling CHF 105 million (about €115 million) with lead investors including Kurma Growth Opportunities Fund and Angelini Ventures.
Amount Raised
CHF26.4 Million
Round Type
Series B
BaselBiotechnologyHealth CareTherapeuticsInvestors
Description
Nuclidium AG has closed an oversubscribed extension of CHF 26.4 million to its Series B round, raising a total of CHF 105 million (around €115 million). The round was led by existing investors Kurma Growth Opportunities Fund and Angelini Ventures along with others. With the fresh capital, Nuclidium aims to accelerate the clinical development of its radiotheranostics. The funds will also support the expansion of its global manufacturing and supply network.
Quick answer
Nuclidium raised CHF26.4 Million in a Series B round, dated May 28, 2026. Investors: Wellington Partners, DeepTech & Climate Fonds, Angelini Ventures, Neva SGR, Bayern Kapital, Eib Co Investment Facility Aurea, Kurma Growth Opportunities Fund and Vives Partners. Nuclidium is based in Basel, Basel City, Switzerland.
- How much did Nuclidium raise?
- Nuclidium raised CHF26.4 Million in a Series B round on May 28, 2026.
- Who invested in Nuclidium?
- Wellington Partners, DeepTech & Climate Fonds, Angelini Ventures, Neva SGR, Bayern Kapital, Eib Co Investment Facility Aurea, Kurma Growth Opportunities Fund and Vives Partners are named as investors in this round.
- What does Nuclidium do?
- Nuclidium is a clinical-stage biotechnology company based in Basel, Switzerland, developing innovative copper-based radiopharmaceuticals for the diagnosis and treatment of cancer.
- Where is Nuclidium based and how big is it?
- Nuclidium is based in Basel, Basel City, Switzerland. Fundz records about 27 employees.
- Who are the decision-makers at Nuclidium?
- Fundz holds 2 contacts at Nuclidium, including the Head of Clinical Operations. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Nuclidium that raised within 45 days of this round, from Fundz verified event records.
- Privo Technologies raised $1.2M (Grant) on July 12, 2026.
- Alchemab Therapeutics raised $33M (Series A) on July 8, 2026.
- Respiro Diagnostics raised $1.3M (Pre-Seed) on July 8, 2026.
- Allotera Therapeutics raised $35M (Funding Round) on July 8, 2026.
- Cyllene raised $38M (Series C) on July 7, 2026.
- Healome Therapeutics raised $2.7M (Seed) on July 7, 2026.
Who to call at Nuclidium, and when
A new round usually means Nuclidium is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nuclidium raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nuclidium, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nuclidium. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nuclidium raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansNuclidium raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.